Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook
7.12.2020 13:09:00 EET | Business Wire | Press release
Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook. With over 26 years’ experience partnering with start-up to mid-size biotech and pharmaceutical companies, Veristat excels in supporting complex trials across a wide range of therapeutic areas. Always taking a patient-centric approach, the company is highly innovative and formulates flexible solutions that benefit patients and attract them to participate in clinical trials.
“In today’s digital world, patients proactively participate in their health plans and seek information on various diseases and treatments online,” stated Shaheen Limbada, Executive Vice President, Global Clinical Operations at Veristat, “Realizing this, we’ve focused on targeting the potential and intended participants for trials through digital media and online platforms. Veristat curates highly relevant and appropriate patient populations by leveraging in-house, customized marketing, and search engine optimization strategies. These strategies improve patient recruitment and retention success rates for trials efficiently and cost-effectively.”
Responding rapidly to the COVID-19 situation and taking a thoughtful scientific approach towards it, Veristat has expanded virtual ecosystems for clients specific to their needs ensuring continuity of ongoing and new clinical trials. The company has developed a “rescue study methodology,” comprised of a series of non-conventional good clinical practice (GCP) compliant tactics for supporting trials. By setting up virtual sites, Veristat ensures the continuity of studies by allowing patients to participate in trials remotely through telemedicine patient portals and at-home visits. Access to the required equipment and medical supplies promptly enabled patients to continue the programs and clients to begin new programs. The company safeguarded patient recruitment throughout the pandemic with its rescue strategies. This included web console technology for staff to interact, patient portals for patients and physicians to communicate via telemedicine, and secure document exchange portals for the collection of study documentation.
Applying knowledge from the various COVID-19 trials that they have conducted, Veristat established a COVID taskforce to centralize the lessons learned and to leverage the most successful approaches on the different trials to focus the trial activities to achieve the highest enrollment. “We are continuously working on advancing the trials in a productive and impactful way unique for each clinical setting to ensure we respond to a highly elevated sense of urgency due to the pandemic and evolving client needs,” stated Patrick Flanagan, Chief Executive Officer at Veristat.
Click here for access to the full interview on Pharma Tech Outlook.
About Veristat:
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, cell and gene therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005104/en/
Contact information
Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Private Markets Firms Face SPV Execution Pressure as LP Demands Rise3.6.2026 15:30:00 EEST | Press release
As private markets firms navigate a more challenging fundraising and exit environment, limited partners (LPs) are demanding greater transparency, stronger governance rights, and more flexible SPV arrangements from fund managers. In fact, 86% of private markets professionals report increased LP requests for tailored SPV structures over the past 12 months, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC¹ surveyed 410 senior private markets practitioners across private equity, private credit, real estate, and infrastructure to examine how investor demands are reshaping SPV structures, operating models, and execution requirements. The findings are detailed in CSC’s new report SPV Global Outlook 2026: How LP demands and operational complexity are reshaping the SPV model. The research reveals that enhanced transparency and reporting is now the leading LP demand, cited by 76% of respondents. Stronger governance and approval
New Evidence Offers Hope for Ketogenic Therapy in Treatment of Anorexia Nervosa3.6.2026 15:00:00 EEST | Press release
A pilot study published today in Communications Medicine demonstrates the potential of a new approach to treating anorexia nervosa — a disorder for which effective treatments have been significantly limited. The research from UC San Diego School of Medicine reports that a ketogenic nutritional intervention — a high-fat, low-carbohydrate, moderate-protein diet — was feasible and safe for patients with weight-normalized and mildly underweight anorexia nervosa. The ketogenic intervention was well-tolerated by participants, with high adherence rates and no significant weight loss observed throughout the program. Furthermore, significant improvements were observed in eating disorder symptoms, with nearly 3 in 4 of study completers in the recovered range at study end, no longer meeting criteria for an anorexia nervosa diagnosis, and all completers experiencing an improvement in depression scores. This press release features multimedia. View the full release here: https://www.businesswire.com
NetApp and Cisco Collaboration Strengthens Defense-in-Depth for Enterprise Cyber Resilience3.6.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Cisco (NASDAQ: CSCO), today announced an expansion of their collaboration to help customers strengthen defense-in-depth strategies for customers. Combining Intelligent Data Infrastructure with advanced analytics and observability capabilities, NetApp and Splunk have delivered deep, real-time visibility into storage and infrastructure health. Together, they are helping customers turn operational data into actionable insights that improve reliability, security, and business outcomes. By expanding their collaboration with the new NetApp Splunk Security Orchestration, Automation, and Response (SOAR) playbook, NetApp and Splunk are helping joint customers contain ransomware attacks and limit data loss at the storage layer, enhancing the containment of the blast radius of cyberattacks while increasing the speed and reducing the cost of recovery. “With AI accelerating both the speed and sophistication of cyberattacks, th
NetApp and Cisco Accelerate and Secure AI Innovation3.6.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Cisco (NASDAQ: CSCO) today announced that they have collaborated to offer new validated solutions for secure, scalable, and simplified AI. Expanding the proven success of FlexPod, the new solutions provide a simple, reliable path for enterprises to address the specific challenges AI workloads place on compute, network, and storage infrastructure. “As IT teams are tasked with delivering reliable, consistent performance across environments, AI workloads are placing increasing demands on their data infrastructure,” said Dallas Olson, Chief Commercial Officer at NetApp. “NetApp and Cisco’s longstanding partnership on FlexPod has already proven effective, saving customers up to 20 percent of their time in infrastructure management and maintenance. Now, we are applying our combined expertise to modern challenges to accelerate AI adoption while reducing risk with built-in security.” NetApp and Cisco are expanding FlexPod
NIQ Named 2026 Retail & Consumer Goods Snowflake Product Partner of the Year3.6.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ) today announced that it has been named the 2026 Retail & Consumer Goods Snowflake Product Partner of the Year award recipient by Snowflake, the AI Data Cloud company. NIQ was recognized for its achievements at Snowflake’s annual user conference, Snowflake Summit 26, for delivering scalable, cloud-native solutions on Snowflake that enable retailers, brands, and media partners to securely enrich data, measure performance, and unlock more precise, actionable commerce intelligence. Through Snowflake’s AI Data Cloud, NIQ helps joint customers collaborate across organizations, activate high-value data assets, and power advanced measurement while maintaining strong governance and data privacy controls. By embedding NIQ’s AI-driven data, models, and harmonization capabilities within Snowflake, customers can unify fragmented datasets into a trusted, scalable foundation for AI. This makes it easier to operationalize AI-powered decision-making and move faster from insight to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
